Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)

• Status: Withdrawn
• Trial end date: 2022-01-01

Summary

This is a multi-center, open-label, randomized Phase 2 trial evaluating PDR001 in two arms for concurrent chemoradiation and consolidation in the treatment-naïve patients with locally advanced, unresectable stage III NSCLC. Patients will be randomized in a 1:1 ratio (arm A and arm B):

• Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen.

• Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen.

• Phase: Phase 2

Details

• Lead Sponsor: Yonsei University
• Treatments: Albumin-Bound Paclitaxel; Antineoplastic Agents; Carboplatin; Cisplatin; Etoposide; Etoposide phosphate; Paclitaxel; Spartalizumab